{"entity":{"id":"scfv-vhh-formats","kind":"term","name":"Single-chain and single-domain antibody fragments","aka":["scFv and VHH","single-chain variable fragment","VHH antibody domain","single-domain antibody fragment"],"tldr":"An antibody recognition unit can be engineered from linked heavy- and light-chain variable regions or from a single suitable variable domain. These formats have different structures to evaluate.","summary":"The original single-chain Fv work linked antibody heavy- and light-chain variable regions and tested binding after expression and refolding. Camelid heavy-chain antibody studies established a different architecture without light chains, underlying VHH-derived formats. More recent engineered-cell comparisons test the behavior of particular fragments in particular constructs. Format names describe architecture; they do not by themselves establish stability, specificity or therapeutic superiority. The first single-chain Fv joined the heavy- and light-chain variable domains of an anti-digoxin antibody with a 15-amino-acid linker (relative molecular mass 26,354); after refolding it showed digoxin specificity like the Fab and an association constant (3.2 x 10^7 per molar) about six-fold below the Fab's (Huston et al., 1988). Camel serum was found to contain IgG-like molecules of about 100 kDa made of heavy-chain dimers without light chains or CH1 (Hamers-Casterman et al., 1993). The NCBI imaging database entry gives about 150 kDa for an intact antibody and 25 to 30 kDa for a monovalent scFv; a 2021 review gives nanobody masses as low as about 15 kDa. Antigen-independent scFv clustering caused tonic signalling and exhaustion in specified CAR constructs (Long et al., 2015).","asOf":"2026-11-10","links":[{"label":"Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli.","url":"https://doi.org/10.1073/pnas.85.16.5879"},{"label":"Naturally occurring antibodies devoid of light chains.","url":"https://doi.org/10.1038/363446a0"},{"label":"Antibody format matters: A comparative analysis of VHH and scFv domains reveals superior in vivo CAR T cell function with VHH domains.","url":"https://doi.org/10.1016/j.ymthe.2026.06.017"},{"label":"Long et al., 2015: 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","url":"https://doi.org/10.1038/nm.3838"},{"label":"NCBI MICAD: L36-Cy5 anti-laminin trimerbody (2004), formats and sizes","url":"https://pubmed.ncbi.nlm.nih.gov/20641540/"},{"label":"Bathula et al., 2021: nanobodies, the future of antibody-based immune therapeutics","url":"https://doi.org/10.1089/cbr.2020.3941"},{"label":"Ward et al., 1989: isolated immunoglobulin variable domains","url":"https://doi.org/10.1038/341544a0"},{"label":"Roux et al., 1998: nurse-shark NAR structure","url":"https://doi.org/10.1073/pnas.95.20.11804"},{"label":"Greenberg et al., 1995: shark antigen-receptor gene family","url":"https://doi.org/10.1038/374168a0"}],"tags":[],"related":["antibody","binder-format-constraints","binder-targeting-module"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Definitions. A conventional antibody pairs heavy- and light-chain variable domains to form a binding site. A single-chain variable fragment (scFv) joins those two domains with a peptide linker in one polypeptide chain, so single-chain does not mean one variable domain (Huston et al., 1988, a 15-amino-acid linker). VHH is the binding domain of a camelid heavy-chain-only antibody (Hamers-Casterman et al., 1993), and an isolated VHH used as a binder is called a nanobody (Bathula et al., 2021). Not every engineered single-domain antibody derives from a camelid VHH, a point the source lesson makes without a primary citation in this batch.","Neither isolated format carries an antibody constant region. Huston's sFv is VH, linker and VL only, and camel heavy-chain IgGs lack CH1 (Hamers-Casterman et al.), so effector recruitment needs other components. A CAR also needs transmembrane and signalling regions, so the binder alone is not the receptor, and a binder, a CAR and a CAR-bearing cell are different objects.","Size and consequences. An intact antibody is about 150 kDa and a monovalent scFv 25 to 30 kDa according to the NCBI imaging-database entry, which describes scFv as clearing faster from blood and penetrating tumours better; the Huston sFv measured 26,354 Da, and a nanobody review gives masses as low as about 15 kDa (Bathula et al.). These are properties of the soluble protein. A cell carrying a small binder does not penetrate tissue like a small soluble protein. A source lesson gives 25 to 27 kDa and 12 to 15 kDa, which differ from the ranges in the sources it cites.","Affinity versus avidity across formats. Affinity is one interaction and avidity the combined strength of several, so joining domains changes the number and geometry of contacts (Ways and Parham, 1983). Format itself shifts binding: the first sFv had an association constant about six-fold below the parent Fab (Huston et al.). Compare matched formats rather than assuming that a multivalent molecule has better intrinsic affinity.","Inference lesson. Two binders that both bind a purified protein have been shown equivalent in that one interaction only. As CARs, one may express poorly on T cells and the other may signal without target cells, a pattern linked to antigen-independent scFv clustering (Long et al., 2015). Surface expression, target-dependent signalling, unwanted activation, tumour killing and healthy-tissue recognition each need separate evidence. Format names describe architecture, not stability, specificity or superiority.","Single-domain antibody is a broader format than camelid VHH. Ward et al. (1989) isolated murine heavy-chain variable domains that bound antigen without an accompanying light-chain variable domain. Roux et al. (1998) showed independent antigen-recognition domains in nurse-shark NAR, which does not associate with light chains. The variable domain is distinct from the full NAR receptor, which also has constant domains (Greenberg et al., 1995). These examples do not make every single-domain binder a camelid VHH."],"category":"Biology basics"},"route":"/terms/scfv-vhh-formats/","neighbours":{"term":[{"id":"antibody","kind":"term","name":"Antibody","route":"/terms/antibody/"},{"id":"binder-targeting-module","kind":"term","name":"Binders as targeting modules","route":"/terms/binder-targeting-module/"},{"id":"binder-format-constraints","kind":"term","name":"Format-dependent binder function","route":"/terms/binder-format-constraints/"},{"id":"immune-product-evidence","kind":"term","name":"Immune measurements and product evidence","route":"/terms/immune-product-evidence/"}]}}